The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Initial results from NEXUS-01, a phase 1 study of LY4052031, an antibody-drug conjugate targeting Nectin-4, in participants with advanced or metastatic urothelial carcinoma.
 
Gopa Iyer
Consulting or Advisory Role - AstraZeneca; Biohaven Pharmaceuticals; EMD Serono; Flare Therapeutics; Janssen; Loxo/Lilly; Mirati Therapeutics
Research Funding - AADi (Inst); Flare Therapeutics (Inst); Janssen (Inst); Loxo/Lilly (Inst); Pfizer (Inst)
Other Relationship - DAVA Oncology
 
Xin Gao
Honoraria - OncLive
Consulting or Advisory Role - 858 Therapeutics; Abeona Therapeutics; ADC Therapeutics; Dendreon; Flare Therapeutics; Hinova Pharmaceuticals; Janssen; Kanaph Therapeutics; Loxo/Lilly
Research Funding - Acerand Therapeutics (Inst); ALX Oncology (Inst); Aprea Therapeutics (Inst); Aravive (Inst); Arvinas (Inst); Bayer (Inst); Exelixis (Inst); Halda Therapeutics (Inst); Harpoon therapeutics (Inst); Janux Therapeutics (Inst); Loxo/Lilly (Inst); Merck (Inst); Novartis (Inst); Nuvation Bio (Inst); Pfizer (Inst); Poseida therapeutics (Inst); Regeneron (Inst); Takeda (Inst); TopAlliance BioSciences Inc (Inst)
 
Alexander Wei
Honoraria - Telix Pharmaceuticals
Consulting or Advisory Role - Lilly
Speakers' Bureau - Merck
Research Funding - IDEAYA Biosciences (Inst); Novartis (Inst); Regeneron (Inst)
 
Inkeun Park
Consulting or Advisory Role - Amgen; Astellas Pharma Korea; BMS pharmaceutical Korea; Boryung Pharmaceuticals; Chong Kun Dang Pharmaceutical Co; daiichi sankyo korea; Janssen; Merck; Ono Pharmaceutical; Samsung Bioepis
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Boryung Pharmaceutical Co (Inst); Chong Kun Dang Pharmaceutical Co. (Inst)
 
Kei Muro
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; Lilly; MSD; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Chugai Pharma; Ono Pharmaceutical
Research Funding - Amgen (Inst); Chugai Pharma (Inst); MSD (Inst); PRA Health Sciences (Inst); Taiho Pharmaceutical (Inst)
 
Peter O'Donnell
Honoraria - Abbvie; Advarra; American Society for Clinical Pharmacology & Therapeutics; AmerisourceBergen; Astellas Pharma; Axiom Healthcare Strategies; CLD, Inc.; Curio Science; EMD Serono; Health Advances; ImmunityBio; IntrinsiQ; Loxo/Lilly; Med IQ; MedLearning Group; Medscape; Merck; Parexel International Corp; Pfizer; Research to Practice; Thermo Fisher Scientific; Vaniam Group
Research Funding - Acerta Pharma (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Janssen (Inst); Loxo/Lilly (Inst); Merck (Inst); Pfizer (Inst); Seagen (Inst)
Expert Testimony - Hart Wagner LLP
Travel, Accommodations, Expenses - Astellas Pharma; Curio Science; Merck; NAMCP; Pfizer
Other Relationship - Dragonfly Therapeutics; Duke University; G1 Therapeutics; Janssen; Nektar
 
Benjamin Garmezy
Consulting or Advisory Role - Abbvie (Inst); Adaptimmune (Inst); Adicent Therapeutics (Inst); AIQ Global (Inst); Amgen (Inst); Arcus Biosciences (Inst); Arvinas (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); EMD Serono (Inst); Exelixis (Inst); Genentech/Roche (Inst); Janssen (Inst); Merck (Inst); Monte Rosa Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Rondo Therapeutics (Inst); Seagen (Inst); Specialty Networks (Inst); Takeda (Inst); Xencor (Inst)
Research Funding - Abbvie (Inst); Accutar Biotech (Inst); Adcentrx Therapeutics (Inst); Adicet Therapeutics (Inst); Amgen (Inst); Arcus Biosciences (Inst); Arvinas (Inst); AstraZeneca (Inst); Avenzo Therapeutics (Inst); AVEO (Inst); Bicycle Therapeutics (Inst); crispr therapeutics (Inst); Eikon Therapuetics (Inst); Envision Pharma Group (Inst); Exelixis (Inst); Flare Therapeutics (Inst); Halda Therapeutics (Inst); Harbour BioMed (Inst); HiberCell (Inst); IDEAYA Biosciences (Inst); Janssen Oncology (Inst); Janux Therapeutics (Inst); Jubilant Therapeutics (Inst); Kineta (Inst); Kinnate Biopharma (Inst); Loxo (Inst); Merck (Inst); MiNK Therapeutics (Inst); Novartis (Inst); Nuvation Bio (Inst); Pfizer (Inst); ProfoundBio (Inst); Roche/Genentech (Inst); Takeda (Inst); Teon Therapeutics (Inst); Tmunity Therapeutics, Inc. (Inst); Xencor (Inst); Zenshine (Inst)
 
Matthew Galsky
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; EMD Serono; Gilead Sciences; Janssen; Merck; Pfizer
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - METHODS AND COMPOSITIONS FOR TREATING CANCER AND RELATED METHODS. MOUNT SINAI SCHOOL OF MEDICINE July 2012 Application number: 20120322792
 
Anthony Joshua
Consulting or Advisory Role - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Eisai (Inst); Grey Wolf Therapeutics (Inst); IDEAYA Biosciences (Inst); Ipsen (Inst); IQvia (Inst); Janssen Oncology (Inst); Mayne Pharma (Inst); Medison (Inst); Merck Serono (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst); Starpharma (Inst)
Research Funding - AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Immunocore (Inst); Janssen Oncology (Inst); Lilly (Inst); Lilly (Inst); Mayne Pharma (Inst); Merck Sharp & Dohme (Inst); Myeloid Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Cancer therapeutic methods; Use of Darovasertib for Neoadjuvant treatment ocular Melanoma
 
Amita Patnaik
Honoraria - Texas Society of Clinical Oncology (TxSCO)
Consulting or Advisory Role - Bayer; Biotheyx; Bristol-Myers Squibb (I); Daiichi Sankyo, Inc.; Genentech/Roche (I); Gilead Sciences; HalioDx; Ionova; Janssen; Loxo; Merck; MERCK (I); Novartis; Pfizer; Pfizer; Quanta Therapeutics; Scorpion Therapeutics; Seagen; Silverback Therapeutics
Speakers' Bureau - Merck; San Antonio Pancreatic Cancer Symposium
Research Funding - 1200 Pharma (Inst); AADi (Inst); Abbvie (Inst); Alpine Immune Sciences (Inst); Ambrx (Inst); Amgen (Inst); Arcus Biosciences (Inst); Arcus Ventures (Inst); Arvinas (Inst); Astellas Pharma (Inst); BioNTech (Inst); BioTheryX (Inst); Bolt Biotherapeutics (Inst); Carrick Therapeutics (Inst); Compugen (Inst); Corvus Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Daiichi-Sankyo (Inst); Ensem (Inst); Exelixis (Inst); Five Prime Therapeutics (Inst); Fochon Pharmaceuticals (Inst); Forty Seven (Inst); Genentech (Inst); Gilead Sciences (Inst); IGM Biosciences (Inst); Infinity Pharmaceuticals (Inst); Institut de Recherches Internationales Servier (I.R.I.S) (Inst); Ionova (Inst); Ionova (Inst); Klus Pharma (Inst); KSQ Therapeutics (Inst); Lilly (Inst); Livzon (Inst); Loxo (Inst); Loxo@Lilly (Inst); Merck (Inst); Moderna Therapeutics (Inst); MOMA Therapeutics (Inst); Nektar (Inst); NiKang Therapeutics (Inst); Olema Oncology (Inst); Ottimo (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Pionyr (Inst); Plexxikon (Inst); Prelude Therapeutics (Inst); Pyrotec Therapeutics (Inst); Quanta Therapeutics (Inst); Roche (Inst); Sanofi (Inst); Scorpion Therapeutics (Inst); Seagen (Inst); Seagen (Inst); SERVIER (Inst); Surface Oncology (Inst); Symphogen (Inst); Syndax (Inst); Tesaro (Inst); Upsher-Smith (Inst); Vigeo Therapeutics (Inst); Vividion Therapeutics (Inst)
 
Nehal Lakhani
Consulting or Advisory Role - Janssen Oncology
Research Funding - Adcentrx (Inst); Alexo Therapeutics (Inst); Alkermes (Inst); Alkermes/Mural Oncology (Inst); Alpine Immune Sciences (Inst); Alpine Immune Sciences (Inst); ALX Oncology (Inst); Apexian Pharmaceuticals (Inst); Arcus Ventures (Inst); Artios (Inst); Ascentage Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); BeiGene (Inst); BioNTech SE (Inst); BioNTech SE (Inst); Biosplice (Inst); Bright Peak Therapeutics (Inst); Bristol-Myers Squibb/Celgene (Inst); Celgene (Inst); Celgene (Inst); Circle Pharma (Inst); Constellation Pharmaceuticals (Inst); Coordination Therapeutics (Inst); CytomX Therapeutics (Inst); Day One Biopharmaceuticals (Inst); Epizyme (Inst); Forty Seven (Inst); Genmab (Inst); Genmab (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Helsinn Therapeutics (Inst); Ikena Oncology (Inst); Ikena Oncology (Inst); Incyte (Inst); InhibRx (Inst); Innovent Biologics (Inst); Janssen (Inst); Jounce Therapeutics (Inst); KSQ Therapeutics (Inst); LAM Therapeutics (Inst); Lilly (Inst); Livzon (Inst); Loxo (Inst); Macrogenics (Inst); Merck (Inst); Mersana (Inst); Northern Biologics (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Quanta Therapeutics (Inst); Regeneron (Inst); Repare Therapeutics (Inst); Revolution Medicines (Inst); Roche (Inst); Sapience Therapeutics (Inst); Sapience Therapeutics (Inst); Seagen (Inst); Servier (Inst); Shattuck Labs (Inst); SK Life Sciences (Inst); Symphogen (Inst); Tesaro (Inst); Tizona Therapeutics, Inc. (Inst); Treeline Biosciences (Inst); Treeline Biosciences (Inst); Treeline Biosciences (Inst)
 
Alejandro Falcon Gonzalez
Consulting or Advisory Role - AstraZeneca; Menarini Group; MSD; Pfizer; Roche/Genentech; Steve
Speakers' Bureau - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Dr. Reddy's Laboratories; Eisai; Gilead Sciences; Grunenthal; Lilly; Novartis; Pfizer; Roche/Genentech; Seagen
 
Daniel Castellano Gauna
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; GlaxoSmithKline; Ipsen; Janssen Oncology; Lilly; MSD Oncology; Novartis; Pfizer; Roche/Genentech
Research Funding - Janssen Oncology (Inst)
Travel, Accommodations, Expenses - AstraZeneca Spain; Bristol-Myers Squibb; Novartis; Pfizer; Roche
(OPTIONAL) Uncompensated Relationships - GUARD cosortium. President Executive board
 
Alexander Philipovskiy
Research Funding - Abbvie (Inst); Abbvie (Inst); Astellas Pharma (Inst); BeiGene (Inst); Frontier Med (Inst); GlaxoSmithKline (Inst); Immuneering (Inst); Janssen Research & Development (Inst); Loxo/Lilly (Inst); Monte Rosa Therapeutics (Inst)
 
Justin Call
No Relationships to Disclose
 
Abhishek Tripathi
Consulting or Advisory Role - Deka biosciences; Gilead Sciences; Pfizer; Systimmune
Speakers' Bureau - Janssen (I); Sanofi
 
Amy Chang
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Elizabeth Martin
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Hongmei Han
Employment - Lilly
Stock and Other Ownership Interests - Lilly; Pfizer; Revolution Medicines
 
Thomas Powles
Honoraria - Astellas Pharma; AstraZeneca; BMS GmbH & Co. KG; Eisai; Exelixis; Incyte; Ipsen; Johnson & Johnson/Janssen; MashupMD; Merck; Merck Serono; Novartis; Pfizer; Roche; Seagen
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Exelixis; Incyte; Ipsen; Johnson & Johnson; MashupMD; Merck; Merck Serono; MSD; Novartis; Pfizer; Roche; Seagen
Research Funding - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Exelixis; Ipsen; Johnson & Johnson; Merck Serono; MSD; Novartis; Pfizer; Roche; Seagen
Travel, Accommodations, Expenses - AstraZeneca; Ipsen; MSD; Pfizer; Roche